{"id":5859,"date":"2025-03-07T17:01:13","date_gmt":"2025-03-07T14:01:13","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=5859"},"modified":"2025-03-07T17:01:13","modified_gmt":"2025-03-07T14:01:13","slug":"summary-of-the-acc-aha-2025-acs-guidelines-update","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/summary-of-the-acc-aha-2025-acs-guidelines-update\/","title":{"rendered":"Summary of the ACC\/AHA 2025 ACS Guidelines Update"},"content":{"rendered":"
Summary of the ACC\/AHA 2025 ACS Guidelines Update<\/div>\n
<\/div>\n
The American College of Cardiology (ACC) and the American Heart Association (AHA), in collaboration with other medical societies, have released a comprehensive guideline for the management of Acute Coronary Syndromes (ACS). This marks the first unified guideline covering STEMI and NSTE-ACS since separate guidelines were issued in 2013 and 2014. The document incorporates the latest evidence, offering updated recommendations on revascularization, imaging, mechanical support devices, transfusion strategies, and secondary prevention.<\/div>\n
<\/div>\n
Key Updates and Recommendations<\/div>\n
<\/div>\n
\u2705 Revascularization Strategies<\/div>\n
\u2022 Complete revascularization (including nonculprit arteries) is now a Class 1 recommendation for both STEMI and NSTE-ACS.<\/span><\/div>\n
\u2022 Preference is given to completing revascularization in a single procedure, rather than a staged approach.<\/span><\/div>\n
\u2022 Intracoronary imaging (IVUS\/OCT) has been upgraded to Class 1 for left main and complex lesions, based on new RCT data showing improved stent-related and clinical outcomes.<\/span><\/div>\n
<\/div>\n
\u2705 Mechanical Circulatory Support (Impella Device)<\/div>\n
\u2022 Impella CP (Abiomed\/Johnson & Johnson MedTech) is reasonable (Class 2a) for patients with severe or refractory cardiogenic shock in STEMI.<\/span><\/div>\n
\u2022 This recommendation follows positive findings from the DanGer Shock Trial, though concerns about procedural risks prevented a Class 1 rating.<\/span><\/div>\n
<\/div>\n
\u2705 Transfusion Strategies for ACS Patients<\/div>\n
\u2022 Based on the MINT trial, liberal red blood cell transfusion may improve some outcomes in MI patients with anemia.<\/span><\/div>\n
\u2022 The guideline provides a Class 2b recommendation for transfusions to maintain hemoglobin \u226510 g\/dL in non-bleeding patients with acute or chronic anemia.<\/span><\/div>\n
<\/div>\n
\u2705 Antiplatelet Therapy & Bleeding Risk Reduction<\/div>\n
\u2022 Dual Antiplatelet Therapy (DAPT) with aspirin + P2Y12 inhibitor remains a Class 1 recommendation for at least 12 months in low bleeding risk patients.<\/span><\/div>\n
\u2022 Bleeding risk reduction strategies:<\/span><\/div>\n
\u2022 Use of proton pump inhibitors (PPIs) in patients at risk for GI bleeding.<\/span><\/div>\n
\u2022 Ticagrelor monotherapy may be considered one month after PCI in patients who tolerate DAPT.<\/span><\/div>\n
\u2022 In patients needing long-term anticoagulation, stopping aspirin 1-4 weeks post-PCI and continuing with a P2Y12 inhibitor (preferably clopidogrel) plus anticoagulant is recommended.<\/span><\/div>\n
<\/div>\n
\u2705 Secondary Prevention & Lipid Management<\/div>\n
\u2022 Fasting lipid panel should be conducted 4-8 weeks after starting or adjusting lipid-lowering therapy (Class 1).<\/span><\/div>\n
\u2022 LDL cholesterol \u226570 mg\/dL despite maximum statin therapy:<\/span><\/div>\n
\u2022 Class 1: Add ezetimibe, evolocumab, alirocumab, inclisiran, or bempedoic acid to lower MACE risk.<\/span><\/div>\n
\u2022 Class 2a: Consider adding non-statin therapy for LDL 55-69 mg\/dL.<\/span><\/div>\n
\u2022 Cardiac rehabilitation before discharge is strongly recommended (Class 1), with home-based programs as a reasonable alternative (Class 2a).<\/span><\/div>\n
<\/div>\n
\u2705 Class 3 Recommendations (Not Recommended)<\/div>\n
\u2022 Routine manual aspiration thrombectomy during PCI in STEMI due to lack of benefit.<\/span><\/div>\n
\u2022 Routine PCI of non-infarct-related arteries in patients with cardiogenic shock, as it increases mortality and renal failure.<\/span><\/div>\n
\u2022 Routine use of glycoprotein IIb\/IIIa inhibitors due to high bleeding risk without clear ischemic benefits.<\/span><\/div>\n
<\/div>\n
Conclusion<\/div>\n
<\/div>\n
This ACC\/AHA 2025 guideline is a rigorous synthesis of the best available evidence, reflecting the latest advances in ACS management. As guideline chair Dr. Sunil Rao emphasized, implementing Class 1 recommendations can significantly improve patient outcomes, while avoiding outdated Class 3 practices ensures safer, more effective care.<\/div>\n
<\/div>\n
\ud83d\udd17 Source: Todd Neale, \u201cACC\/AHA Release New Comprehensive ACS Guidelines,\u201d TCTMD, February 27, 2025.<\/p>\n<\/div>\n
Download PDF file\u00a0<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Summary of the ACC\/AHA 2025 ACS Guidelines Update The American College of Cardiology (ACC) and the American Heart Association (AHA), in collaboration with other medical societies, have released a comprehensive guideline for the management of Acute Coronary Syndromes (ACS). This marks the first unified guideline covering STEMI and NSTE-ACS since separate guidelines were issued in […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5859","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=5859"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5859\/revisions"}],"predecessor-version":[{"id":5860,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5859\/revisions\/5860"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=5859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=5859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=5859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}